Business Wire

Baxter Launches First 3-in-1 Set for Use in Continuous Renal Replacement Therapy and Sepsis Management Protocols

VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in acute care therapies, announced today the commercial launch of a new indication for the company’s oXiris set, which ...
Reuters

China approves Baxter's $4 billion bid for Gambro

BEIJING (Reuters) - China's Ministry of Commerce has approved Baxter International Inc's $4 billion bid for Sweden's Gambro AB provided Baxter sells its global continuous renal replacement therapy ...
Nasdaq

M&A News: Baxter Sells Kidney Care Unit to Carlyle for $3.8B

Baxter International (BAX) has agreed to sell its Kidney Care unit to private equity investment company, Carlyle Group (CG) for $3.8 billion. The company will receive roughly $3.5 billion in cash and ...
AOL

Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome

Baxter International Inc. BAX recently received the FDA’s 510(k) clearance for its ST Set used in continuous renal replacement therapy (“CRRT”). The system is expected to offer additional options to ...